ECTE Financial Facts
Loss from operations: -1.81MDerivative warrant liability gain (loss): 3.68M
See Full Income Statement
Total stockholders' equity: -6.29M
Prepaid expenses and other current assets: 229.23K
See Full Balance Sheet
Echo Therapeutics (ECTE) Earnings
|
Expand Research on ECTE
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +9.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -14.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/14/15 | Q215 | -$0.97 | N/A | N/A | N/A | N/A | N/A |  | | Details | |
8/14/14  |
Q214 | -$0.31 | -$0.23 | -$0.08 | $19.1M | $22.56M | N/A | | | Details | |
| 5/10/13 | Q113 | -$0.13 | -$0.10 | -$0.03 | N/A | $10K | N/A | | | Details | |
| 11/8/11 |
Q311 | -$0.04 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 11/8/12 | Q312 | -$0.11 | -$0.09 | -$0.02 | $30.9K | $40K | N/A | | | Details | |
| 5/11/12 | Q112 | -$0.08 | -$0.07 | -$0.01 | $30.93K | $80K | N/A | | | Details | |
| 8/10/12 | Q212 | -$0.08 | -$0.07 | -$0.01 | $30.9K | $190K | N/A | | | Details | |
| 8/12/11 | Q211 | -$0.06 | -$0.06 | $0.00 | $121.46K | $100K | N/A | | | Details |
